- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Tirzepatide Suppresses NF- κB Gene Expression in Colorectal Cancer Cells In Vitro | ||
| The Medical Journal of Basrah University | ||
| Volume 44, Issue 1, April 2026 PDF (473.79 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.33762/mjbu.2026.191450 | ||
| Authors | ||
| Nasrin Mohammed Fadhil; Jawad Hasan AlBazzoni; Zeenah W Atwan | ||
| Abstract | ||
| Background: Overweight and obesity prevalence have surged globally between 1990 and 2021. One billion males and 1.11 billion females are either overweight or obese. Aim of the study: This study investigates the in vitro effect of the dual glucose dependent insulinotropic polypeptide and Glucagon-like peptide-1 GIP/GLP-1 receptor agonist Tirzepatide on the gene expression of nuclear factor kappa B (NF-κB), a transcription factor critically involved in inflammation and carcinogenesis. Given the potential link between incretin-based therapies and cancer risk, we hypothesize that Tirzepatide might upregulate NF-κB. Methods: Colorectal SW48 cells were treated with three concentrations of Tirzepatide (0.05, 0.5, and 5 µg/µl) for 24 hours. RNA was extracted, cDNA was synthesized, and gene expression was quantified using qPCR. Results: Contrary to the initial hypothesis, results demonstrated a significant, dose-dependent downregulation of NF-κB gene expression. The most substantial suppression (0.03-fold change) was observed at the 0.5 µg/µl concentration, suggesting a non linear, optimal dose-response relationship. These findings indicate that Tirzepatide exerts a direct anti-inflammatory effect by inhibiting NF-κB signaling in a controlled cellular environment. The observed suppression contrasts with clinical concerns, suggesting that any associated cancer risk may arise from secondary, systemic pathological factors rather than a direct oncogenic effect of the drug. | ||
| Keywords | ||
| Colorectal Cancer; in vitro; Tirzepatide; obesity; DM | ||
|
Statistics Article View: 143 PDF Download: 108 |
||